Search results for "Prostate cancer"
showing 3 items of 413 documents
Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT
2021
Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) in metastatic castration-resistant prostate cancer (mCRPC), some patients show worsening disease during PSMA-RLT. We investigated the value of combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in this setting. In n = 29 mCRPC patients with worsening disease after a median of four cycles of [177Lu]Lu-PSMA-617 RLT, combined [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging was performed to detect [18F]FDG-avid lesions with low or no PSMA expression (mismatch lesions). To evaluate prognostic implication of mismatch, survival analyses regarding presence, location, and [18F]FDG PET-derived para…
Characterization of the metabolic profile and identification of potential therapeutic targets in advanced prostate cancer patients
2023
INTRODUCCIÓN El cáncer de próstata (CaP) representa el segundo tumor en incidencia en hombres y es la quinta causa de muerte por cáncer a nivel global. El CaP es un tumor hormono-dependiente, que requiere de la activación del receptor de andrógenos (AR) para su proliferación. Clínicamente, se caracteriza por una gran variabilidad en su evolución, progresando desde una condición indolente hasta un fenotipo agresivo que puede diseminarse y metastatizar a los nodos linfáticos y huesos. Actualmente, el diagnóstico temprano del CaP se realiza mediante la determinación sérica del antígeno prostático específico (PSA) y el examen rectal digital (DRE). Si estas pruebas dan resultados anómalos y hay …
Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid
2007
Bisphosphonates offer a significant improvement in the quality of life for cancer patients; these potent inhibitors of bone resorption have been shown to markedly reduce the morbidity frequently resulting from bone metastases. Despite the success of bisphosphonates as therapeutic agents, however, toxicity in the form of osteonecrosis of the jaw (ONJ) is a rare complication whose incidence rate has climbed in recent years. ONJ is defined as an unexpected development of necrotic bone in the oral cavity, and is commonly associated with administration of the bisphosphonates Pamidronate and Zoledronate. Clinical features include local pain, soft-tissue swelling, and/or loose teeth; ONJ is also o…